241 related articles for article (PubMed ID: 16710741)
1. Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen.
Zhao KJ; Cheng H; Zhu KJ; Xu Y; Chen ML; Zhang X; Song T; Ye J; Wang Q; Chen DF
Arch Dermatol Res; 2006 Jul; 298(2):64-72. PubMed ID: 16710741
[TBL] [Abstract][Full Text] [Related]
2. [The construction and immune response of fusion DNA vaccine CRT180/HPV6E7].
Zhao KJ; Cheng H; Xu Y; Zhu KJ; Chen ML; Zhang X; Song T; Wang Q; Chen DF
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 38(4):573-7. PubMed ID: 17718414
[TBL] [Abstract][Full Text] [Related]
3. [HPV DNA vaccines expressing recombinant CRT/HPV6bE7 fusion protein inhibit tumor growth and angiogenic activity].
Xu Y; Cheng H; Zhao KJ; Zhu KJ; Zhang X
Bing Du Xue Bao; 2007 Nov; 23(6):466-70. PubMed ID: 18092684
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.
Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Ling M; Wu TC
J Clin Invest; 2001 Sep; 108(5):669-78. PubMed ID: 11544272
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
[TBL] [Abstract][Full Text] [Related]
7. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
8. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
[TBL] [Abstract][Full Text] [Related]
9. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
Peng S; Trimble C; Ji H; He L; Tsai YC; Macaes B; Hung CF; Wu TC
J Biomed Sci; 2005 Oct; 12(5):689-700. PubMed ID: 16200349
[TBL] [Abstract][Full Text] [Related]
10. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
[TBL] [Abstract][Full Text] [Related]
11. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules.
Li H; Ou X; Xiong J
Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
Gomez-Gutierrez JG; Elpek KG; Montes de Oca-Luna R; Shirwan H; Sam Zhou H; McMasters KM
Cancer Immunol Immunother; 2007 Jul; 56(7):997-1007. PubMed ID: 17146630
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccines against HPV-16 E7-expressing tumour cells.
De Marco F; Hallez S; Brulet JM; Gesché F; Marzano P; Flamini S; Marcante ML; Venuti A
Anticancer Res; 2003; 23(2B):1449-54. PubMed ID: 12820408
[TBL] [Abstract][Full Text] [Related]
15. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
Cheung YK; Cheng SC; Sin FW; Xie Y
Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
[TBL] [Abstract][Full Text] [Related]
16. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses.
Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X
Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969
[TBL] [Abstract][Full Text] [Related]
17. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines.
Hauser H; Shen L; Gu QL; Krueger S; Chen SY
Gene Ther; 2004 Jun; 11(11):924-32. PubMed ID: 15085173
[TBL] [Abstract][Full Text] [Related]
18. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
19. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
Dell K; Klein C; Gissmann L
Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
[TBL] [Abstract][Full Text] [Related]
20. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
